| |
| |
|
| Insider
Information: |
Schroeder Theodore R |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
22,996 |
|
|
Indirect Shares
|
117,489 |
|
|
| Direct
Value |
$369,493 |
|
|
|
Indirect Value
|
$46,267 |
|
|
| Total
Shares |
140,485 |
|
|
| Total
Value |
$415,760 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -100.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Cadence Pharmaceuticals Inc |
CADX |
President, CEO, Director |
2014-03-19 |
0 |
2014-03-19 |
0 |
Premium* |
|
|
Hyperion Therapeutics Inc |
HPTX |
Director |
2015-05-07 |
0 |
2014-08-13 |
0 |
Premium* |
|
|
Collegium Pharmaceutical, Inc |
COLL |
Director |
2020-05-20 |
11,007 |
2018-05-24 |
0 |
Premium* |
|
|
Nabriva Therapeutics AG |
NBRV |
Director |
2023-01-29 |
11,989 |
2019-08-27 |
117,489 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
90 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-07-31 |
4 |
D |
$1.10 |
$118 |
D/D |
(107) |
177,432 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-08-06 |
4 |
D |
$1.17 |
$263 |
D/D |
(225) |
177,207 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-08-31 |
4 |
D |
$1.06 |
$113 |
D/D |
(107) |
177,100 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-09-06 |
4 |
D |
$1.11 |
$250 |
D/D |
(225) |
176,875 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-09-14 |
4 |
B |
$1.13 |
$56,500 |
D/D |
50,000 |
226,875 |
2.81 |
% |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-09-30 |
4 |
D |
$1.19 |
$127 |
D/D |
(107) |
226,768 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-10-06 |
4 |
D |
$1.08 |
$243 |
D/D |
(225) |
226,543 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-11-06 |
4 |
D |
$1.33 |
$299 |
D/D |
(225) |
226,211 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-11-30 |
4 |
D |
$0.78 |
$83 |
D/D |
(107) |
226,104 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-12-06 |
4 |
D |
$0.72 |
$162 |
D/D |
(225) |
225,879 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-12-28 |
4 |
B |
$0.57 |
$57,320 |
D/D |
100,000 |
325,879 |
2.81 |
% |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2021-12-31 |
4 |
D |
$0.60 |
$64 |
D/D |
(107) |
325,772 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-01-06 |
4 |
D |
$0.58 |
$157 |
D/D |
(270) |
325,502 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-01-29 |
4 |
D |
$0.45 |
$4,845 |
D/D |
(10,766) |
314,736 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-01-31 |
4 |
D |
$0.48 |
$60 |
D/D |
(125) |
314,611 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-02-06 |
4 |
D |
$0.48 |
$126 |
D/D |
(263) |
314,348 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-02-28 |
4 |
D |
$0.45 |
$56 |
D/D |
(125) |
314,223 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-03-06 |
4 |
D |
$0.43 |
$113 |
D/D |
(263) |
313,960 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-03-31 |
4 |
D |
$0.42 |
$44 |
D/D |
(104) |
313,856 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-04-06 |
4 |
D |
$0.41 |
$90 |
D/D |
(219) |
313,637 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-04-30 |
4 |
D |
$0.31 |
$33 |
D/D |
(107) |
313,530 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-05-06 |
4 |
D |
$0.26 |
$59 |
D/D |
(225) |
313,305 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-05-31 |
4 |
D |
$0.21 |
$22 |
D/D |
(107) |
313,198 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-06-06 |
4 |
D |
$0.20 |
$45 |
D/D |
(225) |
312,973 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Executive Officer |
• • – |
2022-06-30 |
4 |
D |
$0.18 |
$19 |
D/D |
(107) |
312,866 |
0 |
- |
|
90 Records found
|
|
Page 3 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
